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ABSTRACT:  
The prototype tris(1,6-dimethyl-3-hydroxypyridin-4-one) chelator for gallium-68, THPMe, has 
shown great promise for rapid and efficient kit-based 68Ga labelling of PET 
radiopharmaceuticals. Peptide derivatives of THPMe have been used to image expression of 
their target receptors in vivo in preclinical and clinical studies. Herein we describe new 
synthetic routes to the THP platform including replacing the 1,6-dimethyl-3-hydroxypyridin-
4-one N1-CH3 group of THPMe with O (tris(6-methyl-3-hydroxypyran-4-one, THPO) and N1-
H (tris(6-methyl-3-hydroxypyridin-4-one), THPH) groups. The effect of these structural 
modifications on lipophilicity, gallium binding and metal ion selectivity was investigated. 
THPH was able to bind 68Ga in extremely mild conditions (5 min, room temperature, pH 6, 1 
μM ligand concentration) and, notably, in vivo, when administered to a mouse previously 
injected with 68Ga acetate. The 67Ga radiolabelled complex was stable in serum for more than 
7 days. [68Ga(THPH)] displayed a Log P value of -2.40 ± 0.02, less negative than the Log P = 
-3.33 ± 0.02 measured for [68Ga(THPMe)], potentially due to an increase in intramolecular 
hydrogen bonding attributable to the N1-H pyridinone units. Spectrophotometric determination 
of the Ga(III)/Fe(III) complex formation constants for both THPMe and THPH revealed their 
preference for binding Ga3+ over Fe3+, which enabled selective labelling with 68Ga3+ in the 
presence of a large excess of Fe3+ in both cases. Compared to THPMe, THPH showed 
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significantly reduced affinity for Fe3+, increased affinity for Ga3+ and increased radiolabelling 
efficiency. THPO was inferior to both THPH and THPMe in terms of labelling efficiency, but its 
benzylated precursor Bn-THPO (tris(6-methyl-3-benzyloxypyran-4-one) provides a potential 
platform for the synthesis of a library of THP compounds with tunable chemical properties and 
metal preferences. 
Introduction  
Positron emission tomography (PET) is a non-invasive clinical diagnostic technique to 
visualise molecular processes in vivo. Gallium-68 (68Ga) has become a popular radionuclide 
for PET imaging, due to its favourable decay properties, generator-based availability and 
convenient half-life (68 min).1-3 Most 68Ga PET imaging exploits peptides labelled with 68Ga 
via an appropriate bifunctional chelator, to target specific disease-related receptors. 68Ga-
DOTATATE, 68Ga-DOTATOC and 68Ga-DOTANOC, all of which contain peptides targeting 
the somatostatin receptor type II (SSTR2), have become clinical standards for imaging 
neuroendocrine tumours4, while 68Ga-PSMA, containing a Glu-urea-Lys moiety targeting the 
prostate-specific membrane antigen (PSMA, glutamate carboxypeptidase II) shows great 
promise for prostate cancer imaging in clinical trials.5, 6 
An attractive attribute of 68Ga is that, in principle, bifunctional chelators that bind gallium 
rapidly and with high affinity could be used for single-step kit-based radiolabelling, minimising 
handling of radioactivity and avoiding difficult, time-consuming radiosynthesis and 
purification steps.7 For optimal efficiency and convenience at the point of use it is important to 
minimise reaction time, radiation dose to operators and dependency on costly automated 
synthesis equipment. Therefore, an ideal chelator for 68Ga must (i) bind Ga3+ in mild 
conditions, without need for pre-processing of the 68Ga generator eluate or purification of the 
radiolabelled complex; (ii) give complexes of high kinetic/thermodynamic stability that are 
resistant to in vivo transchelation; and (iii) produce a single well-defined radiolabelled species. 
Because the concentration of 68Ga3+ in generator eluates is very low, preference for Ga3+ over 
other metal contaminants in eluates or in equipment used for radiolabelling (vials, syringes 
etc.) is also important to obtain radiotracers with high molar activity. 
Despite efforts to develop suitable chelators (Figure S1) for 68Ga radiolabelling, these ideals 
are only very recently being approached. The tetraazacyclododecane chelator DOTA, used in 
several 68Ga-peptide radiopharmaceuticals, requires harsh radiolabelling conditions (low pH, 
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high temperature) not compatible with sensitive biomolecules, and long reaction times 
unsuitable for the 68 min half-life of 68Ga.8, 9 The triazacyclononane chelator NOTA and its 
phosphinic acid derivatives of the TRAP family represent an advance on DOTA, often 
providing quantitative radiochemical yield (RCY) at room temperature and acidic pH.8, 10, 11 
The “chimeric” DATA chelators, possessing both cyclic and an acyclic nitrogen atoms, can be 
radiolabelled quantitatively with 68Ga over a wide pH range and resist demetallation in the 
presence of transferrin or Fe3+.12, 13 For all these chelators, radiolabelling with 68Ga is hampered 
particularly by the presence of Cu2+.13-15 Zn2+ also competes with Ga3+ for coordination to 
NOTA and DATA ligands.15, 16 The acyclic chelator H2dedpa was radiolabelled with 68Ga at 
room temperature and acidic pH, achieving high molar activities.17  
Another class of Ga3+ ligands with potential to meet the above ideals, is based on siderophores 
and iron chelators, exploiting the similarity between Ga3+ and Fe3+ in terms of charge, ionic 
radius (62 pm for Ga3+ vs 65 pm for high spin Fe3+ 18) and preference for hard oxygen donors. 
The siderophore fusarinine-C (FSC),19 obtained from the fungus Aspergillus fumigatus, 
showed excellent 68Ga radiolabelling giving high molar activity over a wide (3-8) pH range. 
The bacterial siderophore deferoxamine (DFO-B) can also be radiolabelled with 68Ga in a wide 
pH range, but is subject to metal dissociation at low concentration20 and cannot compete 
effectively with other 68Ga chelators.21 The acyclic HBED (N,N-bis(2-
hydroxybenzyl)ethylenediamine-N,N-diacetic acid), employed in a 68Ga PSMA tracer,22 binds 
gallium(III) and iron(III) with very high affinity (Log KGa = 37.73, Log KFe = 36.7423). The 
tris(hydroxypyridinone) chelator THPMe (Figure 1, previously known as CP256 and THP24-31), 
investigated as a 68Ga chelator, was also initially developed as an iron-chelating agent.32 It has 
a tripodal scaffold supporting three pendant 3-hydroxypyridin-4-one (HP) units based on the 
bidentate chelating drug deferiprone (Figure 1). Each arm can coordinate Ga3+ through the 
deprotonated hydroxyl and carbonyl groups.33 THPMe is an efficient gallium chelator, out-
competing other popular chelators21 and achieving quantitative radiolabelling in extremely 
mild conditions without eluate pre-processing or post-labelling purification,24 to produce a 
single [68Ga(THPMe)] species, unlike other chelators such as HBED.21 Bifunctional derivatives 
based on THPMe-amine conjugates (Figure 1) have been used to produce several peptide and 
protein conjugates, with promising results. These include peptides targeting the SSTR226, αvβ3 
integrin,27 the prostate specific membrane antigen (PSMA)28 and small proteins.34 The PSMA-
targeting THPMe conjugate is now in phase 2 trials and routine clinical use in some centres.30, 
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35-37 A dendrimer derivative of THPMe (HP9) has also been developed to achieve higher molar 
activity 68Ga-bioconjugates.29 
 
Figure 1. Hydroxypyridinone-based chelators. Left to right: prototype bidentate ligand 
deferiprone; hexadentate ligand THPMe; THPMe-NH2, the basis of bifunctional derivatives. 
While 68Ga-THPMe-PSMA was comparable to its HBED counterpart in PET imaging of 
tumours28, other derivatives such as the 68Ga-THPMe-TATE and 68Ga-THPMe-RGD3 
demonstrated a lower tumour/non-target organ ratio compared to 68Ga radiotracers based on 
DOTA chelators,27, 31 revealing how different targets may benefit from chelators with different 
chemical properties and, in turn, the potential value of structural variants on this promising 
platform. Another potential concern (albeit not arising in practice so far) is that similarity 
between Fe3+ and Ga3+ may lead to competition with adventitious Fe3+ (from vials, syringe 
needles radiolabelling equipment or generator eluate). Further optimisation of THP ligand 
design is therefore important. Modification at the ring nitrogen offers a straightforward way to 
tailor THP properties such as lipophilicity and hydrogen bonding capability. Previous studies 
on bidentate hydroxypyridinone ligands show that modification at the ring nitrogen is possible 
without significant detriment to their M3+ affinity.33, 38  
Herein we present new synthetic routes to THP ligands, including the new derivative THPH 
(Scheme 1) in which the N-methyl groups have been replaced by hydrogen. The labelling 
efficiency and lipophilicity of [68Ga(THPH)] is compared to its THPMe and 
tris(hydroxypyranone) (THPO) analogues, and the conditional formation constants of the 
Ga(III) and Fe(III) complexes are evaluated, to measure and improve upon the gallium-
selectivity and effectiveness of the prototype THPMe for 68Ga radiolabelling. 
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Results and Discussion 
Synthesis 
Synthesis of the precursor Bn-HPH (4, Scheme 1) from 1 was first attempted using the 
previously reported approach to THPMe synthesis39 (Scheme 1, strategy A), i.e., conversion of 
1 into pyridinone 2 by reaction with ammonia, followed by a Mitsunobu reaction with 
phthalimide and subsequent deprotection of the newly-introduced nitrogen with hydrazine at 
reflux. The Mitsunobu reaction failed to give the desired product, likely due to competition by 
the N1-H group with the phthalimide N-H group for deprotonation and subsequent SN2 reaction 
on the phosphonium-activated alcohol. New synthetic strategies were therefore developed.  
 
Scheme 1. Synthetic pathways evaluated for synthesis of THPH and its tris(hydroxypyranone) 
counterpart THPO.  
In strategy B, the Mitsunobu reaction was performed directly on 1 (to avoid deleterious side 
reactions of the pyridinone N1-H group). The pyranone-pyridinone conversion was then carried 
out on 3, followed by deprotection of the NH2 functionality to give the new primary amine-
containing hydroxypyridinone, Bn-HPH (4). This was coupled with the tripodal tricarboxylic 
acid32 to give Bn-THPH (5) in 15.6 % overall yield.   
In an alternative approach (strategy C), the pyranone-pyridinone conversion was performed 
after assembling the hexadentate tripodal unit. Compound 3 was deprotected to give the 
hydroxypyranone bearing a pendant primary amine, Bn-HPO (7), which was then coupled to 
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the tricarboxylic acid to obtain the benzyl-protected tris(hydroxypyranone) Bn-THPO (8). 
Treatment of 8 with ammonia under pressure to give Bn-THPH (5) was monitored using LC-
MS (Figure 2). The overall yield of Bn-THPH (5) from compound 1 via strategy C (7.3 %), 
was lower than that via strategy B, due to the additional step. However, in strategy C the 
benzylated tris(hydroxypyranone) precursor Bn-THPO holds great promise as a flexible 
platform for synthesising a versatile library of tris(hydroxypyridinone) compounds with 
varying substituents at the pyridyl nitrogen, by reaction with a large excess of the relevant 
primary amine. The LC-MS data shows that the pyranone-to-pyridinone conversion proceeded 
in a step-wise fashion, offering the opportunity to create mixed species containing both 
pyranone and pyridinone units, or mixed pyridinone units. 
Debenzylation of Bn-THPH (5) with BCl3 produced the desired chelator THPH (6) 
quantitatively. The same deprotection procedure applied to Bn-THPO (8) gave the tris(6-
methyl-3-hydroxypyran-4-one) chelator THPO (9) in 78 % yield. 
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Figure 2. LC-MS analysis (total ion current) of the reaction mixture for conversion of Bn-
THPO (8) to Bn-THPH (5) (strategy C) at A) 0 h B) 8 h C) 48 h and D) 72 h. RT: Retention 
time; MA: area; BP: m/z value. Insets: Bn-THPO and MS signal of [Bn-THPO +H]+ (purple), 
mono-substituted Bn-THPO and MS signal (green), di-substituted Bn-THPO and MS signal 
(blue), Bn-THPH structure and MS signal (orange). 
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68Ga radiolabelling and comparison with THPMe and THPO 
THPH, THPMe and THPO were radiolabelled at decreasing ligand concentrations in the same 
mild conditions (5 min, pH 6, room temperature) previously employed for THPMe.24 
Radiochemical yields (RCY) are reported in Table 1 and compared graphically in Figure 3.  
 
Figure 3. Comparison of RCY (average ± standard deviation, N = 3) obtained by 68Ga 
radiolabelling of THPH, THPMe and THPO at decreasing ligand concentration. 
Efficient (> 95%) radiolabelling of THPH achieved at concentrations as low as 1 µM (Table 1), 
was verified by iTLC and HPLC analysis. At a ligand concentration as low as 0.1 μM THPH 
was still able to bind 68Ga in 93.9 % RCY while the RCY for THPMe decreased to 83 %, 
highlighting improved radiolabelling efficiency for the new chelator.  
As was the case for [68Ga(THPMe)], no pre-processing of the generator eluate or post-labelling 
purification was required to obtain a radiochemically pure complex. iTLC showed only one 
species, corresponding to the radiolabelled complex without the presence of colloidal or 
unchelated “free” 68Ga.  Analytical reversed-phase HPLC of the radiolabelling mixture 
(method 3) showed only one signal in the UV-Vis chromatogram (3 min 26 s), attributed to 
excess ligand, and one in the radiochromatogram at 4 min 56 s attributed to [68Ga(THPH)]. 
HPLC analysis of non-radioactive [natGa(THPH)] also showed a single peak in the UV-Vis 
chromatogram, whose retention time (4 min 20 s) matched that of [68Ga(THPH)] after 
correcting for delay due to the serial configuration of the detectors (Figure 4A). The mass 
spectrum of [natGa(THPH)] confirmed the 1:1 stoichiometry of the complex (Figure S4), and 
no other gallium-containing ions were observed. As was the case for [Ga(THPMe)], low 
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solubility of [natGa(THPH)] prevented further characterisation by 1H/71Ga NMR. Synthesis of 
more soluble conjugates of the ligands is underway to enable NMR studies. 
The tris(hydroxypyranone) ligand THPO was also radiolabelled quantitatively, in the same 
conditions except that significantly higher ligand concentration (100 μM) was required to reach 
quantitative radiolabelling (Table 1). HPLC analysis (method 4) revealed a single peak at 8 
min 18 s, matching the UV peak of [natGa(THPO)] at 7 min 42 s (Figure 4B). 
The observed decreased efficiency in gallium binding was not unexpected for pyranone 
derivatives, whose lower electron density of the heterocyclic ring compared to the pyridinone 
analogues is known to compromise binding to iron.32, 40  
 
Figure 4. Normalised chromatograms of THPH (A) and THPO (B) and their gallium 
complexes. Blue: UV (254 nm) for ligand; Black: UV (254 nm) for natGa complex; Red: 
radiochromatogram for 68Ga complex. The serial configuration of the detectors accounts for a 
36 second delay between UV and radio-chromatograms. 
Determination of the partition and distribution coefficients (Log P and Log D7.4, Table 1) for 
the 68Ga complexes of THPMe and THPH ligands revealed, unexpectedly, higher lipophilicity 
of [Ga(THPH)] than of [Ga(THPMe)], although both complexes were highly hydrophilic. This 
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could be due to [Ga(THPH)] forming intramolecular hydrogen bonds rather than hydrogen 
bonds with the solvent. This phenomenon was previously reported for their bidentate analogues 
and some amido-3-hydroxypyridin-4-one ligands.41-43 As expected, [Ga(THPO)], in which 
oxygen replaces the heterocyclic amine, was more hydrophobic than its pyridinone 
counterparts. This agrees with the above LC-MS results for Bn-THPO and Bn-THPH, where 
sequential replacement of the 3 oxygen atoms with N1-H groups progressively reduced 
retention times. 
 
 [Ga(THPMe)] [Ga(THPH)] [Ga(THPO)] 
Log P -3.33 ± 0.02 -2.40 ± 0.02 -1.64 ± 0.01 
Log D7.4 -3.27 ± 0.02 -2.28 ± 0.05 -1.65 ± 0.03 
 Radiochemical yield 
100 μM 96.9 ± 1.0 98.9 ± 0.7 95.6 ± 0.2 
10 μM 97.8 ± 0.5 99.1 ± 0.2 83.0 ± 0.4 
1 μM 96.7 ± 0.2 98.1 ± 0.4 27.5 ± 0.7 
0.1 μM* 83.0 ± 0.5 93.9 ± 0.4 N/A 
 
Table 1. Log P and Log D7.4 values and RCY, at different ligand concentrations, of 68Ga 
complexes (average ± standard deviation (N = 4 for LogP and LogD7.4, N = 3 for RCY). 
*Radiolabelling performed with 68Ga eluate from a second E&Z generator, eluted with clinical 
grade HCl. 
Serum stability and in vivo studies 
The stability of a radiolabelled chelate in biological environments is critical to its utility in 
radiotracers. [67Ga(THPH)] stability in human serum was determined by size-exclusion HPLC, 
comparing the elution profile of the complex with that of unchelated 67Ga in serum. The longer 
half-life 67Ga was used instead of 68Ga, to allow more prolonged evaluation of stability. 
[67Ga(THPH)] was stable in serum for at least 8 days with no shift in its chromatographic signal 
(retention time: 15 min 30 s) compared to the complex incubated in PBS. When unchelated 
67Ga was incubated in serum, by contrast, 67Ga eluted at 12 min at early serum incubation time 
points (chelated as 67Ga EDTA by EDTA in the mobile phase, Figure S7), but became more 
associated with serum proteins over time: after 8 days incubation two new signals appeared, at 
12 min (67Ga EDTA) and 9 min 30 s (serum proteins). Excellent serum stability has been 
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previously observed for [67Ga(THPMe)], which showed no sign of transchelation after 4 h at 
37 °C.24 
A preliminary evaluation of the behaviour and stability of [68Ga(THPH)] in vivo was performed. 
PET imaging of a SCID beige mouse injected with [68Ga(THPH)] revealed rapid renal excretion 
(Figure 5A). reversed-phase HPLC of urine at 60 min post injection revealed a single 
radioactive species, corresponding to intact [68Ga(THPH)] (4.9 min, Figure 5B). A similar 
biodistribution has been reported for [Ga(THPMe)].24 
 
Figure 5. A) Dynamic PET/CT MIP in a mouse injected with [68Ga(THPH)]. Fast blood 
clearance is evident, with only kidneys and bladder visible in the 15-30 min image. B) 
radioHPLC of urine 60 min after injection (method 3), showing a single peak attributed to 
[68Ga(THPH)] (Figure 4A). 
The ability of THPH to scavenge gallium in vivo was also investigated. Figure 6 shows how 
68Ga biodistribution in a mouse injected with acetate-buffered 68Ga3+ suddenly changed upon 
injection of the chelator: most of the activity previously in the blood pool cleared quickly from 
the blood into the kidneys and the bladder (Figure 6A). HPLC analysis of urine confirmed in 
vivo radiolabelling of the chelator (Figure 6B), showing one peak corresponding to 
[68Ga(THPH)].  This scavenging ability, shared with THPMe (Supplementary information, 
Figure S8), reflects the rapid complexation kinetics and the extraordinary ability to 
transchelate gallium (which is known to bind rapidly and almost completely to transferrin when 
intravenously injected44) rapidly in the biological milieu.  
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Figure 6. A) Dynamic PET/CT MIP of a mouse injected with acetate buffered 68Ga at time 0 
followed by THPH at 30 min. Blood clearance of 68Ga acetate (represented by radioactivity in 
the heart ventricles) is slow in the first 30 min. After the injection of THPH a sudden clearance 
occurs through the kidneys into the bladder. B) RadioHPLC of urine 60 min after 68Ga injection 
(method 3), showing only one peak, attributed to [68Ga(THPH)]. C) Time/activity curves 
showing % ID in heart (as a measure of blood activity), kidneys and bladder as a function of 
time. Each data point represents a 5 min interval defined by its starting time. 
Spectrophotometric determination of conditional formation constants 
The THPMe and THPH acid dissociation and conditional formation constants for their Ga(III) 
and Fe(III) complexes were investigated by spectrophotometric measurements. pKa and pM 
values (defined as -Log[M3+] when [ligand]total = 10 μM, [metal]total = 1 μM and pH = 7.4) are 
reported in Table 2. A full list of the measured conditional formation constants is provided in 
the supplementary information (Tables S1-S3), together with speciation plots calculated for 
the pH range of the titration. The pKa values for THP chelators are better described as intrinsic 
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protonation constants since they represent the average pKa values of the three 
hydroxypyridinone units, which could not be distinguished by UV spectrophotometric 
measurements.45 The first intrinsic pKa is attributed to the carbonyl group of the HP unit, and 
the second to the adjacent hydroxyl group. For THPH a third intrinsic protonation constant, 
associated with deprotonation of the N1-H group in the pyridinone ring, exists outside the pH 
range used. Its pKa3 was estimated to be 13 from the spectral change of the [Fe(THPH)] complex 
in the pH 10-12.5 range. The measured protonation constants for THPH are lower than those 
measured for deferiprone, but slightly higher than those for THPMe (that is, THPMe is slightly 
more acidic than THPH). This was unexpected considering the presence of electron-donating 
N-methyl group and suggests that other chemical interactions (e.g. hydrogen bonding) may be 
influencing the pKa of these compounds.  
 
 THPMe THPH Deferiprone* 
pKa1 3.2** 3.4** 3.5 
pKa2 9.4** 9.5** 9.8 
pKa3 n/a 13.0*** n/a 
pFe 29.1 28.6 20.8 
pGa 30.0 31.8 20.7 
 
Table 2. Acid dissociation and conditional Fe(III) and Ga(III) complex formation constants for 
THPMe and THPH. Estimated overall error for each value < 3%. pM values were calculated 
based on [M]total = 1 µM, [L]total = 10 µM and pH = 7.4. *Previously reported measurements 
on deferiprone33 were repeated here to confirm the reliability of our titration 
method.**Intrinsic pKa values45 were determined from spectrophotometric titration. When 
deviation from the obtained intrinsic pKa values were considered (± 0.2-0.8 log units), no 
significant changes in pM values (less than 3%) were observed. ***Estimated pKa value. No 
significant spectral change was observed between pH 11.5 and 12.5 for pKa titration. Changing 
the estimated pKa value can result in different metal log β values for THPH but no appreciable 
change in pM values. 
 
The data in Table 2 show that THPH has higher affinity than THPMe for Ga(III) but, 
unexpectedly, lower than THPMe for iron. The conditional formation constants indicate that 
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both THPH and THPMe are selective for Ga3+ over Fe3+. This was unexpected considering that 
deferiprone lacks a preference for either metal,33 implying that the tripodal scaffold is critical 
in determining the coordination preferences of these hexadentate chelators. 
Achievement of thermodynamic equilibrium for Ga(III) and Fe(III) complex 
formation/dissociation is a relatively slow process23. Therefore, traditional spectrophotometric 
and potentiometric techniques, which allow only a few minutes equilibration, may produce 
apparent stability constants harbouring a kinetic component. In contrast, batch titrations, with 
equilibration over several days/weeks, generally result in more accurate “true” equilibrium 
stability constants. This discrepancy was recently acknowledged by Notni et al. for [Ga(TRAP-
Pr)].46 In the case of THP chelators, no significant changes in the absorbance spectra were 
observed beyond the equilibration period, suggesting that equilibrium had been reached, 
although changes after longer intervals cannot be excluded. In any case, the use of a short 
equilibration time is particularly relevant for radiopharmaceutical applications, where 
radiolabelling processes must be rapid. 
Competition experiments 
To quantify the preference of the two ligands for Ga3+ over Fe3+ in a radiolabelling setting, a 
competition experiment was performed, where 68Ga radiolabelling of THPMe and THPH in the 
presence of different concentrations of Fe3+ was investigated. Instead of a traditional “no-
carrier-added” radiolabelling mixture, in these competition studies non-radioactive natGa3+ was 
added to 68Ga eluate (to reach a gallium : ligand ratio of approx. 9:10 to introduce competition 
by ensuring that the ligand concentration was sufficient to bind just one of the two metals 
quantitatively). Since 68Ga is chemically indistinguishable from natural gallium and its addition 
negligibly increases the total concentration of Ga3+, the percentage of 68Ga3+ bound to the 
ligand reflects the percentage of total Ga3+ bound to the ligand. To ensure constant pH at 
different metal concentrations, a higher concentration of ammonium acetate buffer than in 
conventional radiolabelling experiments was necessary (final concentration 0.44 M). Upon 
addition of the THP ligand (≈ 1 equivalent, 10 μM) to mixtures of nat/68Ga3+ (0.9 equivalent) 
and Fe3+ (0, 0.9 or 9 equivalents) the radiochemical yield of the radiolabelling mixture was 
measured by iTLC (mobile phase 2) at different time points (Figure 7). 
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Figure 7. Influence of various concentrations of Fe3+ on the radiochemical yield of 
[68Ga(THPMe)] and [68Ga(THPH)] in the presence of 1 equivalent of ligand (10 μM) and 0.9 
equivalent of natGa3+ (average ± standard deviation; for control samples (without Fe) N = 6, 
for other samples N = 3 (error bars are too small to be visible). 
Unexpectedly, under these conditions (unlike conventional radiolabelling conditions) THPMe 
could not reach quantitative radiochemical yield even in the absence of iron, probably because 
the higher buffer and metal salt concentration increases the abundance of competing ligands 
(ammonia, acetate, nitrate) compared to more conventional labelling media. Nonetheless, it is 
clear that despite the presence of insufficient ligand to bind all the Ga3+ and Fe3+, the 68Ga-
labelling efficiency was not dramatically reduced by the presence of even a ten-fold excess 
(compared to ligand) of Fe3+. Notably, the presence of 0.9 equivalents of iron with 0.9 of 
gallium decreased the radiochemical yield for the two ligands only marginally (not significant 
for either ligand at later time points, p = 0.06 for THPMe, p = 0.22 for THPH), indicating that 
iron could not compete effectively with gallium for ligand binding. When the amount of iron 
was increased to 9 equivalents (a ten-fold excess over gallium), still the majority of the ligand 
bound to Ga3+ and not Fe3+, indicating a clear preference of THP ligands for gallium over iron 
(≈ 40 fold preference for gallium over iron under these conditions was estimated considering 
that a ≈ 80:20 gallium : iron complex ratio prevailed when a 10 fold excess of iron over gallium 
was present). This strong preference of both THPMe and THPH for binding Ga3+ over Fe3+ 
indicates that the presence of significant amounts of iron should not adversely affect the 
performance of the chelators during radiolabelling or in vivo. 
A second competition study between THPMe and THPH was conducted, to determine whether 
their different affinities for gallium would affect their relative 68Ga labelling efficiency. The 
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difference in retention factor between the two complexes on iTLC (mobile phase 1) was 
exploited to monitor a solution in which 68Ga was added to an equimolar mixture of the two 
ligands (100 μM each, with equimolarity ensured by integration of the 1H NMR spectrum, 
Figure S6), by sampling at different times after the addition (Figure 8). After one minute the 
radioactivity was already quantitatively chelated, indicating extremely fast radiolabelling for 
both compounds, but with preference for THPH (ratio: 70:30). By 120 min the ratio had 
increased to ≈ 90:10, confirming that gallium binds preferentially to THPH rather than THPMe. 
These data agree qualitatively with the spectrophotometric measurements and suggest that 
binding to both ligands is initially under kinetic control, while the thermodynamic preference 
for THPH is established by 30 min. Interestingly, these results also demonstrate that Ga(III) can 
transchelate from THPMe to THPH under these conditions. While this suggests a degree of 
kinetic lability of the [Ga(THP)] system when excess ligand is present, resistance towards 
transchelation in vivo (where excess ligand is greatly diluted) has been extensively confirmed 
in previous preclinical and clinical studies,24, 26-30 including the present manuscript (Figure 5).  
 
 
Figure 8. iTLCs of the radioactive 68Ga complexes of THPMe and THPH in mobile phase 1 (A) 
and of an equimolar mixture of THPMe and THPH treated with 68Ga3+ in mobile phase 2 (1 min 
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time point) or in mobile phase 1 (1, 10 and 120 min) (B), imaged with a phosphorimager. (C) 
shows how the percentage of activity associated with the two chelators, as calculated from the 
images, changes over time. Data are average ± standard deviation (N = 3, error bars are too 
small to be visible). 
Both spectrophotometric titration and competition experiments show how modification at the 
hydroxypyridinone ring unexpectedly influences the preference of THP chelators for Ga(III) 
vs. Fe(III), whereas a similar effect was not observed for bidentate hydroxypyridinone 
compounds.38 This implies that geometric restrictions imposed by the tripodal structure of the 
ligand are critical to metal ion selectivity. It is likely that replacing the N1-methyl group with 
hydrogen modifies the steric constraints and the degree and type (e.g. intramolecular vs. 
intermolecular) of hydrogen bonding, compared to THPMe. Both these factors could result in 
marked changes in the geometry and rigidity of the coordination sphere, leading to different 
metal affinities and selectivity of the two THP chelators.  
Conclusions 
Despite the acyclic topology of THPMe and THPH, their affinity for Ga3+ is very high (pGa = 
30.0 and 31.8 respectively) and, contrary to our naive expectation, exceeds their affinity for 
Fe3+. The reasons for this preference are unknown, but likely related to geometry constraints 
imposed by the tripodal framework, since no such preference was observed for the bidentate 
chelator deferiprone.33 An important consequence of this selectivity is that the expected 
vulnerability of the THP ligands to competition with iron, during labelling and in vivo, is not 
manifested either in the measurements described here or in the preclinical and clinical uses of 
THPMe described so far.24, 26-30, 35-37 Moreover, minor alteration of the hydroxypyridinone 
moiety (replacing N1-CH3 with N1-H) significantly improves both the affinity for Ga3+ (and 
hence 68Ga radiolabelling efficiency) and the selectivity for Ga3+ over Fe3+ (and hence 
resistance to interference from adventitious iron). The origin of this effect may be related to 
changes in intramolecular hydrogen bonding, which affect the ability of the scaffold to provide 
an idealised octahedral cavity of appropriate size, for as yet unknown reasons. Synthesis of 
more soluble derivatives is underway to allow investigation of these factors by NMR. As well 
as producing THPH as a new tris(hydroxypyridinone) ligand with superior Ga3+-chelating 
properties compared to the established THPMe, we have described a novel synthetic strategy 
that allows further systematic modification of pyridinone nitrogen substituents by using the 
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protected THPO as a common precursor. This opens the door to further tuning of ligand design 
to improve labelling efficiency and modify biological behaviour. 
Experimental section 
Materials and instrumentation 
Chemicals were obtained from Sigma Aldrich, unless otherwise specified, and used without 
further purification. NMR spectra were acquired on a Bruker Advance 400 spectrometer with 
a 5 mm Quattro Nucleus Probe (QNP) at 400.13 MHz. Chemical shifts are referenced to the 
appropriate solvent peak. Positive ion mass spectra were recorded using an Agilent 6510 QTOF 
spectrometer. Analytical reversed-phase LC-MS were acquired on a Thermo Scientific 
Exactive Orbitrap Mass Spectrometer coupled to a Thermo Scientific Accela Pump with CTC 
Autosampler, using a ThermoFisher HyperSil GOLD column (2.1 x 150 mm, 5 m), flow rate 
0.2 mL min-1. Data were acquired and reference mass-corrected via a dual-spray electrospray 
ionisation source, using the factory-defined calibration procedure. Semi-preparative HPLC was 
carried out using an Agilent Eclipse XDB-C18 column (9.4 x 250 mm, 5 μm), flow rate 3 mL 
min-1, and UV detection at 214 nm on an Agilent 1200 LC system. Mobile phase A was water 
with 0.1 % TFA and mobile phase B was acetonitrile with 0.1 % TFA. For method 1, 
concentration of B increased from 0 to 100 % at 1 %/min. For method 2, concentration of B 
increased from 20 % to 100 % in 100 min. Analytical reversed-phase HPLC was performed on 
the same system using an Agilent Eclipse XDB-C18 column (4.6 x 150 mm, 5 μm) with a 1 
mL min-1 flow rate and UV detection at 214 or 254 nm, coupled to a LabLogic Flow-Count 
radioactivity detector with a sodium iodide probe (B-FC-3200). Mobile phase A was water 
with 0.1 % TFA, mobile phase B was acetonitrile with 0.1 % TFA. For methods 3 and 4, UV 
detection was set at 254 nm and isocratic elution was used with 10 % B and 15 % B, 
respectively.  For methods 5 and 6, UV detection was set at 214 nm and gradients included 5 
min of equilibration at 0 % B at the start of the run. For method 5, concentration of B increased 
from 0 % (at 5 min) to 45 % (at 15 min) and subsequently decreased to 0 (at 20 min). For 
method 6, % B increased from 0 % (at 5 min) to 75 % (15 min) and back to 0 % (20 min). Size-
exclusion chromatography was conducted using a BioSep SEC-s2000 column (145 Å, 300 x 
7.8mm, 5 μm) with a mobile phase of PBS with 50 mM EDTA trisodium salt, flow rate 1 
mL/min. 68Ga was obtained from an Eckert & Ziegler 68Ge/68Ga-generator eluted with high-
purity 0.1 M HCl (Fluka Analytical). Instant thin layer chromatography strips (iTLC-SG, 
Varian Medical Systems) were run in two different mobile phases (mobile phase 1: 0.1 M 
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citrate pH 5; mobile phase 2: 1:1 ammonium acetate 2 M : methanol) and visualised using a 
Cyclone Plus Phosphor Imager (Perkin Elmer) and a Raytest Rita-Star TLC scanner. 
Synthesis and characterisation data 
2-Hydroxymethyl-3-benzyloxy-6-methyl-pyran-4(1H)-one (1) was synthesised following 
published procedures.39 THPH was synthesised from 1 employing two different synthetic 
strategies using reactions based on literature methods.32, 39 The tripodal scaffold 4-acetamido-
4-(2-carboxyethyl)heptanedioic acid was synthesised following literature procedures.32 All 
intermediates and final products were characterised by ESI-MS, 1H NMR and 13C NMR 
(Figures S9-S16). 
2-hydroxymethyl-3-benzyloxy-6-methyl-pyridin-4(1H)-one (2) 
A solution of 1 (1.010 g, 4 mmol) in ethanol (5 mL) was sealed in a thick-walled glass vial 
containing 25 % aqueous ammonia (20 mL) and stirred at 75 °C overnight. Addition of 
concentrated HCl to reach neutral pH precipitated white crystals, which were collected by 
filtration and washed with cold water and diethyl ether (0.609 g, 60.6 %). ESI-MS (m/z): 
246.12 [M+H]+ calcd: 246.11 for C14H15NO3 + H+. 1H NMR (methanol-d4, 400 MHz) δ: 2.33 
(s, 3H, C6-CH3), 4.34 (d, 2H, C2-CH2-OH), 5.08 (s, 2H, C3-O-CH2-Ph), 6.33 (s, 1H, C5-H in 
pyridinone), 7.35 (m, 5H, C3-O-CH2-Ph). 13C NMR (Methanol-d4, 100 MHz) δ: 18.7 (C6-
CH3), 57.0 (C2-CH2-OH), 74.6 (C3-O-CH2-Ph) 117.1 (C5-H in pyridinone), 128.0 (o-CH in 
benzyl), 129.4 (p-CH in benzyl), 130.2 (m-CH in benzyl), 138.6 (i-C-CH2 in benzyl), 143.0 
(C2 in pyridinone), 144.7 (C3 in pyridinone), 147.8 (C6 in pyridinone), 176.0 (C4 in 
pyridinone). 
2-phthalimidomethyl-3-benzyloxy-6-methyl-pyran-4(1H)-one (3) 
A solution of 1 (1.05 g, 4.0 mmol), triphenylphosphine (1.395 g, 8 mmol) and phthalimide 
(1.181 g, 8 mmol) in dry tetrahydrofuran (20 mL) under an atmosphere of nitrogen was cooled 
to 0 °C and diethyl azodicarboxylate (2 mL, 8 mmol) was added dropwise. After stirring 
overnight, methanol was added to quench excess diethyl azodicarboxylate prior to solvent 
removal by rotary evaporation. The white residue was recrystallised from methanol affording 
white crystals (1.157 g, 72.3 %). ESI-MS (m/z): 376.11 [M+H]+, calcd: 376.12 for C22H17NO5 
+ H+. 1H NMR (DMSO-d6, 400 MHz) δ: 2.14 (s, 3H, C6-CH3), 4.73 (s, 2H, C2-CH2-N), 5.10 
(s, 2H, C3-O-CH2-Ph), 6.26 (s, 1H, C5-H in pyranone), 7.40 (m, 5H, C3-O-CH2-Ph), 7.89 (m, 
4H, phthalimide). 13C NMR (DMSO-d6, 100 MHz) δ: 19.0 (C6-CH3), 34.4 (C2-CH2-N), 72.9 
(C3-O-CH2-Ph), 114.3 (C5-H in pyranone), 123.4 (C7-H and C4-H in phthalimide), 128.2 (o-CH 
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in benzyl), 128.4 (p-CH in benzyl), 128.5 (m-CH in benzyl), 131.4 (C5-H and C6-H in 
phthalimide), 134.7 (C3a and C7a in phthalimide), 136.8 (i-C-CH2 in benzyl), 142.6 (C2 in 
pyranone), 153.9 (C3 in pyranone), 165.1 (C6 in pyranone) 167.2 (C=O in phthalimide), 174.6 
(C4 pyranone). 
Bn-HPH (2-aminomethyl-3-benzyloxy-6-methyl-pyridin-4(1H)-one) (4) 
A solution of 3 (500 mg, 1.3 mmol) in 7 M ammonia solution in methanol (30 mL) was added 
to a thick-walled glass vial that was sealed and stirred overnight at 75 °C. Aqueous hydrazine 
(55 %, 0.2 mL) was then added to the reaction mixture and the solution heated at reflux for 3 
h. After removal of the solvent by rotary evaporation the brown residue was purified by silica-
gel chromatography (CH2Cl2: MeOH = 80: 20, Rf  = 0.35) to afford Bn-HPH (317 mg, 45 %). 
ESI-MS (m/z): 245.13 [M+H]+, calcd: 245.13 for C14H16N2O2 + H+. 1H NMR (Methanol-d4, 
400 MHz) δ: 2.33 (s, 3H, C6-CH3), 3.60 (s, 2H, C2-CH2-NH2), 5.14 (s, 2H, C3-O-CH2-Ph), 
6.39 (s, 1H, C5-H in pyridinone), 7.36 (m, 5H, C3-O-CH2-Ph). 13C NMR (Methanol-d4, 100 
MHz) δ: 19.4 (C6-CH3), 38.8 (C2-CH2- NH2), 74.6 (C3-O-CH2-Ph) 116.7 (C5-H in pyridinone), 
129.6 (o-CH in benzyl), 129.6 (p-CH in benzyl), 130.4 (m-CH in benzyl), 138.5 (i-C-CH2 in 
benzyl) 143.6 (C2 in pyridinone), 143.8 (C3 in pyridinone), 149.0 (C6 in pyridinone), 174.2 (C4 
in pyridinone). 
 
Bn-THPH (5) (from Bn-HPH) 
4-acetamido-4-(2-carboxyethyl)heptanedioic acid (20 mg, 0.07 mmol), hydroxybenzotriazole 
hydrate (HOBT, 32.7 mg, 0.21 mmol) and dicyclohexylcarbodiimide (DCC, 44 mg, 0.21 
mmol) were dissolved in the minimum amount of N,N-dimethylformamide (DMF, ≈ 1.5 mL) 
and stirred. Bn-HPH (86 mg, 0.35 mmol) was dissolved separately in 500 μL of DMF and 
added to the former mixture, which was then stirred at 50 °C for 48 h. Formation of the product 
over time was monitored via LC-MS (m/z = 968, [M+H]+). DMF was removed under high 
vacuum and the product purified by silica gel chromatography (eluent CH3OH: CHCl3 = 20: 
80 Rf  = 0.25, followed by CH3OH: CHCl3: 40 % aqueous NH3 = 20: 80: 2) to obtain Bn-THPH 
(37 mg, 48 %). ESI-MS (m/z): 968.45 [M+H]+, 990.44 [M+Na]+, calcd: 968.46 for 
C54H61N7O10 + H+. 1H NMR (Methanol-d4, 400 MHz) δ: 1.86 (s, 3H, CH3-CO-NH-tripod), 
1.88 (m, 6H, CH2-CH2-CO-NH-CH2-pyridinone), 2.09 (m, 6H, CH2-CH2-CO-NH-CH2-
pyridinone), 2.28 (s, 9H, C6-CH3), 4.10 (s, 6H, CO-NH-CH2-pyridinone), 5.11 (s, 6H, C3-O-
CH2-Ph), 6.31 (s, 3H, C5-H in pyridinone), 7.35 (m, 15H, C3-O-CH2-Ph). 13C NMR 
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(Methanol-d4, 100 MHz) δ: 18.8 (C6-CH3), 23.6 (CH3-CO-NH-tripod), 30.8 (CH2-CH2-CO-
NH-CH2-pyridinone), 31.0 (CH2-CH2-CO-NH-CH2-pyridinone), 37.7 (CH2-CH2-CO-NH-
CH2-pyridinone), 58.9 (NHC-tripod), 74.5 (C3-O-CH2-Ph) 117.3 (C5-H in pyridinone), 129.5 
(p-CH in benzyl), 130.2 (m-CH in benzyl), 138.5 (i-C-CH2 in benzyl), 141.4 (C2 in 
pyridinone), 144.8 (C3 in pyridinone), 148.0 (C6 in pyridinone), 173.0 (C4 in pyridinone), 176.1 
(CH2-CH2-CO-NH-CH2-pyridinone). 
THPH (6) 
Bn-THPH (17 mg, 0.018 mmol) was dissolved in the minimum amount of methanol (≈ 100 μL) 
and diluted to 1 mL with dichloromethane. An excess of BCl3 (3 mL of a 1 M solution in 
dichloromethane) was added through a cannula (Cole-Parmer) under an atmosphere of N2. 
After 2 hours, the vial was placed on ice and excess methanol was added to quench remaining 
BCl3. Volatiles were removed by rotary evaporation. The residue was redissolved in methanol 
and precipitated by addition of cold diethyl ether to give THPH (3‧ HCl salt) (15.6 mg, 90 % 
yield). ESI-MS (m/z):  698.32 [M+H]+, 349.67 [M+2H]2+, 233.44 [M+3H]3+, calcd: 698.31 
for C33H43N7O10+H+. 1H NMR (D2O, 400 MHz) δ: 1.85 (s, 3H, CH3-CO-NH-tripod), 1.87 (m, 
6H, CH2-CH2-CO-NH-CH2-pyridinone), 2.17 (m, 6H, CH2-CH2-CO-NH-CH2-pyridinone), 
2.47 (s, 9H, C6-CH3), 4.44 (d, 6H, CO-NH-CH2-pyridinone), 6.93 (s, 3H, C5-H in pyridinone). 
13C NMR (D2O, 100 MHz) δ: 17.9 (C6-CH3), 22.6 (CH3-CO-NH-tripod), 28.9 (CH2-CH2-CO-
NH-CH2-pyridinone), 29.2 (CH2-CH2-CO-NH-CH2-pyridinone), 36.6 (CH2-CH2-CO-NH-
CH2-pyridinone), 58.0 (NHC-tripod), 111.7 (C5-H in pyridinone), 136.4 (C2 in pyridinone), 
140.6 (C3 in pyridinone), 146.7 (C6 in pyridinone), 160.9 (C4 in pyridinone), 173.3 (CH3-CO-
NH-tripod), 176.4 (CH2-CH2-CO-NH-CH2-pyridinone). HPLC: a single peak was detected 
using both HPLC methods 3 (λ = 254 nm, 3 min 26 s, Figure 4A) and 5 (λ = 214 nm, 10 min 
45 s, Figure S2). 
Bn-HPO (2-(aminomethyl)-3-(benzyloxy)-6-methyl-4H-pyran-4-one) (7) 
A solution of 3 (499 mg, 1.33 mmol) was dissolved in ethanol (5 mL) and heated at reflux for 
3 h after addition of 5.5 % of aqueous hydrazine (1.5 mL). The pH was adjusted to 1 with 
concentrated HCl (37 %) and the flask cooled to 0 °C. The phthalhydrazide precipitate was 
filtered out and the filtrate was evaporated to dryness. The resulting residue was dissolved in 
water (2 mL) and the pH was adjusted to 10 using concentrated NaOH (10 M). The solution 
was extracted with dichloromethane (4 x 2 mL), the organic layers were combined and the 
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solvent removed by rotary evaporation. The crude product was purified by silica gel 
chromatography (dry loading, CH2Cl2 : MeOH = 90:10, Rf = 0.45) to obtain Bn-HPO (90.0 
mg, 28 % yield). ESI-MS (m/z): 246.11 [M+H]+, calcd: 246.11 for C14H15NO3 + H+. 1H NMR 
(Methanol-d4, 400 MHz) δ: 2.31 (s, 3H, C6-CH3), 3.51 (s, 2H, C2-CH2-NH2), 5.09 (s, 2H, C3-
O-CH2-Ph), 6.27 (s, 1H, C5-H in pyranone), 7.37 (m, 5H, C3-O-CH2-Ph). 13C NMR 
(Methanol-d4, 400 MHz) δ: 19.5 (C6-CH3), 39.3(C2-CH2- NH2), 74.9 (C3-O-CH2-Ph) 115.0 
(C5-H in pyridinone), 129.6 (o-CH in benzyl), 129.7 (p-CH in benzyl), 130.4 (m-CH in 
benzyl), 137.9 (i-C-CH2 in benzyl) 142.3 (C2 in pyranone), 162.9 (C3 in pyranone), 167.9 (C6 
in pyranone), 178.4 (C4 in pyranone). 
Bn-THPO (8) 
The tripodal acid 4-acetamido-4-(2-carboxyethyl)heptanedioic acid (14 mg, 0.049 mmol), 
diisopropylethylamine (25.6 µL, 0.15 mmol) and HATU (55.7 mg, 0.15 mmol) were dissolved 
in the minimum volume of N,N-dimethylacetamide (DMA, ≈ 500 μL), combined while stirring 
and left at room temp for 1 h. A solution of Bn-HPO (52 mg, 0.16 mmol) in DMA (500 μL) 
was then added and the mixture stirred for 72 h. The DMA was removed under high vacuum 
and the product was purified using preparative HPLC (method 1) to obtain Bn-THPO (34.7 
mg, 73.1 % yield). ESI-MS (m/z): 486.21 [M+2H]2+, 971.41 [M+H]+, 993.38 [M+Na]+, calcd: 
971.41 for C54H58N4O13 + H+. 1H NMR (Methanol-d4, 400 MHz) δ: 1.91 (s, 3H, CH3-CONH-
tripod), 1.96 (m, 6H, CH2-CH2-CONH-CH2-pyranone), 2.17 (m, 6H, CH2-CH2-CONH-CH2-
pyranone), 2.29 (s, 9H, C6-CH3), 4.23 (s, 6H, CONH-CH2-pyranone), 5.12 (s, 6H, C3-O-CH2-
Ph), 6.28 (s broad, 3H, C5-H in pyranone), 7.35 (m, 15H, C3-O-CH2-Ph). 13C NMR (Methanol-
d4, 100 MHz) δ: 19.5 (C6-CH3), 23.5 (CH3-CO-NH-tripod), 30.9 (CH2-CH2-CO-NH-CH2-
pyranone), 31.2 (CH2-CH2-CO-NH-CH2-pyranone), 37.3 (CH2-CH2-CO-NH-CH2-pyranone), 
58.9 (NHC-tripod), 75.0 (C3-O-CH2-Ph) 115.2 (C5-H in pyridinone), 129.6 (p-CH in benzyl), 
130.2 (m-CH in benzyl), 138.1 (i-C-CH2 in benzyl), 143.7 (C2 in pyranone), 159.1 (C3 in 
pyranone), 167.9 (C6 in pyranone), 172.9 (C4 in pyranone), 175.7 (CH3-CO 169.4), 178.2 
(CH2-CH2-CO-NH-CH2-pyridinone).  
Bn-THPH (5) (from Bn-THPO) 
Bn-THPO (22.4 mg, 0.023 mmol) was added to 7 M ammonia in MeOH (11 mL) and the 
mixture stirred at 75 °C in a sealed thick glass vial. The reaction was left for 72 h and monitored 
via LC-MS (mobile phase: A = H2O + 0.1 % formic acid, B = acetonitrile + 0.1 % formic acid; 
gradient: 0-5 min 100 % A, 5-55 min from 100 % A to 100 % B, flow rate 0.2 mL/min, mass 
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range 900-1100 m/z). The solvent was then removed under reduced pressure and the residue 
purified by preparative HPLC (method 2) to give Bn-THPH (10.88 mg, 49 % yield). 
THPO (9) 
To Bn-THPO (6.65 mg, 0.007 mmol) in DCM : MeOH (7:1), BCl3 (3 mL of a 1 M solution in 
dichloromethane) was added via a cannula under a N2 atmosphere. After 2 h, the vial was 
placed on ice, the reaction was quenched with MeOH and the solvent was removed under 
reduced pressure. The residue was dissolved in water : acetonitrile (60:40) and purified by 
preparative HPLC (method 1) to give THPO (TFA salt, 5.6 mg, 78 % yield). ESI-MS (m/z): 
702.26 [M+H]+, 723.24 [M+Na]+, 351.13 [M+2H]2+. calcd: 701.27 for C33H41N4O13 + H+. 1H 
NMR (Methanol-d4, 400 MHz) δ: 1.91 (s, 3H, CH3-CO-NH-tripod), 1.99 (t, 6H, CH2-CH2-
CO-NH-CH2-pyranone), 2.22 (t, 6H, CH2-CH2-CO-NH-CH2-pyranone), 2.30 (s, 9H, C6-CH3), 
4.40 (d, 6H, CO-NH-CH2-pyranone), 6.24 (s, 3H, C5-H in pyranone). 13C NMR (Methanol-
d4, 100 MHz) δ: 19.7 (C6-CH3), 23.5 (CH3-CO-NH-tripod), 31.0 (CH2-CH2-CO-NH-CH2-
pyranone), 31.3 (CH2-CH2-CO-NH-CH2-pyranone), 37.3 (CH2-CH2-CO-NH-CH2-pyranone), 
59.0 (NHC-tripod), 112.3 (C5-H in pyranone), 143.5 (C2 in pyranone), 148.9 (C3 in pyranone), 
167.5 (C6 in pyranone), 173.0 (C4 in pyranone), 176.1 (CH3-CO-NH-tripod), 176.4 (CH2-CH2-
CO-NH-CH2-pyranone). HPLC: A single peak was observed with both HPLC methods 4 (λ = 
254 nm, retention time 4 min 43 s, Figure 4B) and 6 (λ = 214 nm, 11 min 10 s, Figure S3). 
Complexation with 68Ga3+ and natGa3+ 
For all the radiolabelling experiments, an Eckert &Ziegler generator was eluted with 5 mL of 
high purity HCl 0.1 M (Fluka analytical) in five 1 mL fractions, whose activity was measured 
by a Capintec radionuclide dose calibrator. 100 μL of the highest activity fraction (15-20 MBq) 
were added to 100 μL of the ligand (concentration range 200-2 μM) in ammonium acetate 
0.5 M. Verification of the radiolabelling was carried out after 5 min by reversed-phase HPLC 
(for THPH: method 3; for THPO: method 4) and iTLC-SG with two different mobile phases, as 
described above (mobile phase 1: Rf [Ga(THPH)] = 0.64 ± 0.02, Rf Gacolloid = 0, Rf 68Gafree= 1; 
mobile phase 2: Rf [Ga(THPH)] = 1, Rf 68Gafree = 0, 68Gacolloid = 0). Radiolabelling of THPH at 
0.1 μM was performed using a second E&Z generator, eluted with clinical grade 0.1 M HCl 
(E&Z). 
The natGa complexes of THPH and THPO were prepared by addition of an aqueous solution of 
Ga(NO3)3 (5 µL, 2 mg/mL, excess) to a solution of the ligand (50 µL, 150 µM) in ammonium 
acetate 0.2 M. After 5 min reaction time, an aliquot of the reaction mixture was applied to a 
  
24 
reversed-phase HPLC column to confirm complex formation (for THPH: method 3, for THPO: 
method 4, see Figure 4A and 4B). [Ga(THPH)] ESI-MS (m/z): 764.22 [M+H]+, 382.61 
[M+2H]2+, 349.66 [M-Ga+4H]2+. Calcd: 764.22 for C33H40N7O10Ga + H+. The spectrum is 
reported in Figure S4. No peaks assignable to stoichiometry other than 1:1 were visible. 
Solubility of the complex in water or any other solvent was not sufficient to obtain a satisfactory 
NMR spectrum or X-ray-quality crystals. 
Lipophilicity determination 
68Ga-radiolabelling of THPMe, THPH and THPO (200 μM in ammonium acetate 0.5 M) was 
performed as described above and verified by iTLC-SG. An aliquot (10 μL) of each 
radiolabelling mixture was then added to vials containing a pre-equilibrated mixture of 
octanol/water (500/490 μL) for Log P measurements, or octanol/PBS (500 μL/490 μL) for Log 
D7.4 measurements. The mixtures were vortexed and then shaken for 30 min before separation 
of the two phases by centrifugation (4000 rpm, 3 min). The activity in aliquots of each phase 
(20 μL aqueous phase, 100 μL octanol phase) was measured in the gamma-counter and 
corrected for the different volumes sampled. Each experiment was repeated 4 times. 
Spectrophotometric determination of conditional formation constants 
The automated titration system consists of a Metrohm 765 Dosimat autoburette, a Mettler 
Toledo MP230 pH meter with SENTEK pH electrode (P11), and an HP 8453 UV-visible 
spectrophotometer with a Hellem quartz flow cuvette, with circulation driven by a Gilson Mini-
plus #3 pump (speed capability 20 mL/min). A potassium chloride electrolyte solution (0.1 M) 
was used to maintain the ionic strength. The temperature of the test solutions was maintained 
in a thermostatic jacketed titration vessel at 25 ± 0.1 °C, using a Fisherbrand Isotemp water 
bath. The pH electrodes were calibrated using the software GLEE47 with data obtained by 
titrating a volumetric standard HCl (0.1 M) in KCl (0.1 M) with KOH (0.1 M) under an 
atmosphere of argon. Analytical grade reagent materials were used in the preparation of all 
solutions. The solution under investigation was stirred vigorously during the experiment. For 
pKa determinations, a cuvette path length of 10 mm was used, while for metal stability constants 
determinations, a cuvette path length of 50 mm was used (experimental concentration was ca. 
40 μM for iron complexes and ca. 10 μM for gallium complexes). All instruments were 
interfaced to a computer and controlled by an in-house program. 
The automated titration adopted the following strategy: the pH of a solution was increased in 
increments of 0.1 pH unit by the addition of potassium hydroxide solution (0.1 M) from the 
  
25 
autoburette. The pH readings were judged stable if they varied by less than 0.01 pH unit after 
a pre-set incubation period. For pKa determinations, an incubation period of 1.5 min was 
adopted; for metal stability constant determinations, an incubation period of 3 min was adopted. 
The cycle was repeated until the predefined end point pH value was achieved. Titration data 
were analysed with the HypSpec2014 program48, 49 (http://www.hyperquad.co.uk/). The fitting 
spectra range for iron complexes was 400-700 nm while that for gallium complexes was 250-
350 nm. pH values higher than 11.3 (outside the pH range in which electrode measurements 
are considered accurate) were neglected and re-calculated from the added KOH quantity (using 
“no pH” mode within the HypSpec2014 program).  The associated hydrolysis constants used 
in the analysis were collected from Martell’s critical stability constants.50 Metal affinities of 
compounds in this study were determined in competition with the metal hydrolysis species in 
a solution at a high pH (titrated up to pH 12.5). Satisfactory fitting of the THPMe titration for 
both iron and gallium were achieved. In contrast, the titration of THPH was found to be more 
complex due to the presence of the additional protonation sites. A satisfactory result for the 
THPH/gallium interaction was achieved, but not for iron, which is possibly related to different 
log stability constants of [Fe(OH)4]- and [Ga(OH)4]-  (Log β = 34.4 and 39.4 respectively50). 
Instead, the corresponding stability constant was obtained using EDTA-iron-hydroxide species 
competition at the high pH range following a slightly modified titration procedure (cuvette path 
length: 100 mm, incubation period: 30 min, experimental concentration of iron complexes: ca. 
20 μM, experimental concentration of EDTA: ca. 50 mM). Speciation plots (Tables S1-S3) 
were calculated with the HYSS program.51  
Ligand competition for 68Ga3+ binding 
A solution containing both THPMe and THPH, each 2 mM, in D2O was diluted to 100 μM with 
aqueous ammonium acetate (0.5 M) after NMR analysis had been used to confirm equal 
concentration of the two compounds (Figure S5). 50 μL of the mixture were mixed with an 
equal volume of 68Ga eluate. The percentage of radioactivity associated with each compound 
was measured by iTLC-SG (mobile phase 1 and 2) at different time points (1, 5, 10, 30, 60 and 
120 minutes). 
Metal competition for THP binding 
A standard ICP-MS solution of iron(III) in nitric acid (Alfa Aesar) was diluted in 0.1 M nitric 
acid (Fluka analytical) to obtain 2250 μM and 225 μM Fe(III) solutions. The same procedure 
was used to prepare a 225 μM Ga(III) solution from its ICP-MS standard solution (Sigma 
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Aldrich). The Ga(III) solution (20 μL, 225 μM) was mixed with the Fe(III) solution (20 μL, 
225 or 2250 μM Fe) or with 0.1 M nitric acid as a control (20 μL) and the 68Ga generator eluate 
was added (20 μL, [Ga3+] ≈ 2 nM and was considered negligible). The relevant THP ligand 
(440 μL of a 11.3 μM solution in 0.5 M ammonium acetate buffer) was added to the 
radiolabelling mixture (final concentration: [THP] = 10 μM, [Ga3+] = 9 μM, [Fe3+] = 0, 9 or 90 
μM). The radiochemical yield at different times was measured by iTLC-SG (mobile phase 2). 
Statistical analysis was performed using a t-test between the “no Fe” and “0.9 eq Fe” groups. 
[67Ga(THPH)] serum stability 
67Ga chloride (50 μL, 5 MBq), obtained from Nordion (Canada), was added to THPH (50 μL, 
100 μM) in 0.5 M ammonium acetate. Quantitative radiolabelling was verified after 5 min of 
incubation, via iTLC-SG. The retention time on a size-exclusion HPLC (mobile phase: PBS 
with 50 mM EDTA trisodium salt) was 15 min 30 s for [67Ga(THPH)]. The retention time for 
67Ga chloride in the same conditions was 12 min. An aliquot of each solution (60 μL) was 
added to male AB human serum (600 μL, Sigma) and incubated at 37 °C. Size-exclusion 
radiochromatography was performed after 1 h, 1 day and 8 days incubation. 
In vivo studies with THPH 
All in vivo experiments complied with guidelines on responsibility in the use of animals in 
bioscience research of the U.K. Research Councils and Medical Research Charities, under U.K. 
Home Office project and personal licences. Male SCID/beige mice (7 months old, Charles 
River) were used for preliminary animal studies on THPH. Dynamic PET scanning was 
performed using a nanoScan® PET/CT (Mediso Medical Imaging Systems).52 Respiration rate 
and bed temperature were monitored throughout. PET/CT datasets were reconstructed using 
the Monte-Carlo-based full 3D iterative algorithm Tera-Tomo (Mediso Medical Imaging 
Systems).53 All reconstructed datasets were analysed using VivoQuant 1.21 software 
(inviCRO), which enables the co-registration of PET and CT images and the delineation of 
regions of interest (ROIs) for quantification of activity in specific organs. Mice were 
anaesthetised with isoflurane (O2 flow rate of 1.0-1.5 L/min and isoflurane levels of 2-2.5 %) 
cannulated at the tail vein using a catheter (25 μL volume) and a CT scan was performed. 
Subsequently, a PET scan was started and the radiotracer injected. One mouse (37 g) was 
injected with of a [68Ga(THPH)] solution (307 μL, 5 μM, 6.59 MBq) and imaged for 1 hour to 
determine biodistribution and in vivo stability of the radiolabelled complex. A second mouse 
(33 g) was injected with acetate buffered 68Ga (100 μL, 0.1 M ammonium acetate, 4.68 MBq), 
  
27 
without THPH or other chelator, while scanning, followed at 30 min by an injection of THPH 
(50 μL of a 50 μM solution in PBS). Animals were then sacrificed by neck dislocation while 
still anaesthetised. Urine was collected and analysed by reversed-phase HPLC (method 3). 
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ABBREVIATIONS 
CT: computed tomography 
DCC: dicyclohexylcarbodiimide  
EDTA: ethylenediaminetetraacetic acid 
FSC: fusarinine-C 
HBED: N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid 
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HOBT: hydroxybenzotriazole  
HP: 3-hydroxypyridin-4-one 
HPLC: high performance liquid chromatography  
iTLC-SG: instant thin-layer chromatography-silica gel 
MIP: maximum intensity projection 
PBS: phosphate-buffered saline 
PET: positron emission tomography 
PSMA: prostate specific membrane antigen 
RCY: radiochemical yield 
SSTR2: somatostatin receptor type II 
THP: tris(3-hydroxypyridin-4-one) 
THPO: tris(6-methyl-3-hydroxypyran-4-one) 
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